Machine Learning and Traditional Analysis of the Interaction Between Cardiovascular Diseases and Haematological Malignancies - European Medical Journal

Machine Learning and Traditional Analysis of the Interaction Between Cardiovascular Diseases and Haematological Malignancies

2 Mins
Cardiology
Authors:
Tal Caller,1 Alexander Fardman,3 Efrat Sharon,1 Nili Naftali-Shani,1,2 Jonathan Leor,1 Elad Maor,3 *Tomer Itkin1,2
  • 1. Neufeld and Tamman Cardiovascular Research Institute, The Olga & Lev Leviev Cardiothoracic and Vessels Center, Sheba Medical Center, Faculty of Medical and Health Sciences, Tel Aviv University, Israel
  • 2. Sagol Center for Regenerative Medicine, Department of Pathology, Faculty of Medical and Health Sciences, Tel Aviv University, Israel
  • 3. Department of Cardiology, The Olga & Lev Leviev Cardiothoracic and Vessels Center, Sheba Medical Center, Ramat Gan, Israel
*Correspondence to [email protected]
Disclosure:

The authors declare no conflicts of interest.

Citation:
EMJ Cardiol. ;12[1]:38-40. https://doi.org/10.33590/emjcardiol/MCFY9542.
Keywords:
Cancer risk factors, cardiovascular disorders, haematological malignancies, reverse cardio-oncology.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

INTRODUCTION

Cardiovascular disorders (CVD) and clonal haematopoiesis of indeterminate potential, the very early state with developmental potential of haematological malignancies, exhibit reciprocal interactions.1,2 While the presence of clonal haematopoiesis of indeterminate potential confers a risk for heart failure, it is unclear if CVDs are associated with elevated risk in development of haematological malignancies.

MATERIALS AND METHODS

In the authors’ preliminary study, to determine the association between CVDs and the risk for haematological cancer, they evaluated 27,231 adults. These individuals, who participated in a preventive healthcare screening programme between 2000–2018, were free of CVD and cancer at baseline. Each participant underwent a complete physical evaluation, blood test, and exercise stress test at baseline. CVD was defined as ischaemic heart disease, stroke, atrial fibrillation, or hypertension. Machine learning and traditional survival analyses were applied to evaluate the association between CVD and haematological cancer. For machine learning, the team used the random forest method using Curat package in r, and incorporated all continuous variables gathered into the model (70% training, 30% test). For survival analysis, they first matched each patient with CVD to a control patient by propensity scores to balance for age, sex, smoking, diabetes, renal function, BMI, and length of follow-up. Then, patients with and without CVD were compared using Cox proportional hazard regression.

RESULTS

Using machine learning, they found that the strongest features associated with haematological cancer in the cohort were low estimated glomerular filtration rate, age, high atherosclerosis cardiovascular disease score, and BMI. Of note, systolic and diastolic blood pressure were also strongly associated with haematological cancer. Next, the team successfully matched 5,500 patients with CVD to controls with a median follow-up of 9.2 years (interquartile range: 5–15 years). During follow-up, 1,380 individuals developed cancer. Of them, 186 individuals developed haematological cancer.

They used Cox proportional hazard regression and the Kaplan Mayer method to determine the risk and hazard ratio of developing haematological cancer. Compared with subjects without CVD, patients with CVD were 91% more likely to develop cancer during follow-up, and 62% more likely to develop haematological cancer (hazard ratio: 1.61; 95% CI: 1.21–2.16). Moreover, the 10-year risk of developing haematological cancer was 1.9% for patients with CVD and 1.0% for individuals without CVD. Notably, the increased incidence of haematological cancers included 38% increase in cases of leukaemia but only 11% increase in cases of lymphoma.

CONCLUSION

Herein, by applying machine learning and traditional analysis, the authors show that CVD risk and CVDs are associated with increased incidence of haematological cancer. Their previous study demonstrated, in murine models, that CVDs promote existing solid tumour growth via release of blood-carried factors.3 It was shown in murine models that CVDs modulate the bone marrow microenvironment, affecting haematopoietic developmental lineage trajectories.4,5 Thus, they hypothesise a model in which CVDs modulate the human bone marrow microenvironment via secretion of blood-carrying factors. Transformed marrow microenvironment may display plasticity properties that can potentially augment accelerated development of haematological malignancy from a pre-tumorigenic state (Figure 1).

Figure 1: Illustration of hypothetical model for the flow of events by which cardiovascular diseases augment development of haematological malignancies.
The model is based on recent findings and the authors’ results, demonstrating that CVDs are a risk factor for development of haematological malignancies. In the course of CVD pathogenesis, as part of the heart repair efforts cardiac cells alter their secretome and release factors, that are potentially tissue-transformative, into the blood. Upon arrival to the bone marrow, these factors modify cells in the microenvironment in a way that is potentially supportive for development of haematological malignancies from haematopoietic cells in a pre-tumorigenic state. This figure was generated using Biorender.com. CVD: cardiovascular disease.

Currently, basic research studies are conducted to confirm this hypothesis. Deciphering the action mechanisms between CVDs and haematological malignancies could lead to therapeutic advances in cardiovascular and cancer treatment and may ultimately improve patient outcomes.

References
Fuster JJ et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842-7. Jaiswal S et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26): 2488-98. Caller T et al. Small extracellular vesicles from infarcted and failing heart accelerate tumor growth. Circulation. 2024;149(22):1729-48. Courties G et al. Ischemic stroke activates hematopoietic bone marrow stem cells. Circ Res. 2015;116(3):407-17. Itkin T, Rafii S. Cardiovascular diseases disrupt the bone-marrow niche. Nature. 2022;601(7894):515-7.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.